Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leukocyte interleukin - CEL-SCI

Next Previous
Drug Profile

Leukocyte interleukin - CEL-SCI

Alternative Names: BC-IL; Buffy coat interleukins - CEL-SCI; Interleukin-2 cocktail - CEL-SCI; Leucocyte Interleukin injection - CEL-SCI; Multikine

Latest Information Update: 21 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CEL-SCI Corporation
  • Developer CEL-SCI Corporation; Ergomed; Naval Medical Research Center; Orient Europharma; Teva Pharmaceutical Industries
  • Class Antineoplastics; Antiretrovirals; Antivirals; Granulocyte-macrophage colony-stimulating factors; Interferons; Interleukins
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Head and neck cancer
  • Phase I Cervical dysplasia
  • No development reported Condylomata acuminata
  • Discontinued Breast cancer; HIV infections; Prostate cancer

Most Recent Events

  • 13 Aug 2025 CEL-SCI Corporation submits a Breakthrough Medicine Designation application for Leukocyte Interleukin to the Saudi Food and Drug Authority (SFDA)
  • 09 Jul 2025 CEL-SCI enters into an agreement with an Undisclosed company in Saudi Arabia to collaborate on both regulatory and commercial efforts for leukocyte interleukin (Multikine) in the treatment of head & neck cancer, in Saudi Arabia
  • 21 May 2025 CEL-SCI Corporation plans to submit a Breakthrough Medicine Designation application for Leukocyte Interleukin to the Saudi Food and Drug Authority (SFDA)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top